Rosetta OncoGxOne

Rosetta Genomics has launched OncoGxOne, Admera Health's next-generation sequencing panel that detects a vast number of genetic alterations implicated in cancer to provide actionable clinical recommendations. OncoGxOne interrogates all types of genomic aberrations in 64 genes, specifically 56 related to targeted cancer therapies and eight related to chemotherapy. The test covers all exons and 5' and 3' UTRs for each gene, as well as introns that harbor potential gene translocation breakpoints, Rosetta said. The laboratory-developed test is performed on formalin-fixed, paraffin-embedded tissue.